PJ27
PJ27 is a dual PD-1/PD-L1/JAK1 inhibitor, with an IC50 of 414 nM against PD-1/PD-L1, an IC50 of 786 nM against JAK1, a Ka of 294 nM for human PD-1/PD-L1, and a Ka of 473 nM for murine PD-1/PD-L1. PJ27 promotes the infiltration of CD3+CD8+ and CD3+CD4+ cells into the tumor microenvironment and exerts a significant immune activation effect. PJ27 inhibits tumor growth in a dose-dependent manner in the LLC lung cancer mouse model. PJ27 is applicable to relevant research on lung cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C38H40N8O2
- Masse moléculaire:640.78
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
JAK3 786 nM (IC50) |
PJ27 (0.125-2 μM; 48 h) enhances Jurkat T cell-mediated killing of PD-L1-expressing A549 cells, with significant A549 viability reduction at 2 μM in co-culture[1].
PJ27 binds to human and murine PD-L1 with comparable affinity, with Kd values of 294 nM and 473 nM respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549, Jurkat T cells
-
Concentration:0, 0.125, 0.25, 0.5, 1, 2 μM
-
Incubation Time:48 h
-
Result:Showed almost no inhibitory activity against A549 or Jurkat T cells cultured alone.
Significantly decreased A549 cell viability at 2 μM in co-culture model.
Enhanced Jurkat T cell-mediated killing of A549 cells in co-culture model.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 5 to 6 weeks old, subcutaneous inoculation of 1 × 106 LLC cells)[1]
-
Dosage:25 mg/kg; 50 mg/kg
-
Administration:i.p.; daily; 11 days
-
Result:Achieved a tumor growth inhibition rate (TGI) of 21% and reduced phosphorylated STAT3 (p-STAT3) levels in tumor tissues compared to control at 25 mg/kg.
Achieved a TGI of 56%, reduced p-STAT3 and PD-L1 levels in tumor tissues, increased the percentage of CD3+CD8+ cytotoxic T cells in tumor tissues to 38.8% (vs.
16.3% in control), and increased the percentage of CD3+CD4+ helper T cells in tumor tissues to 50.5% (vs.
28.9% in control) at 50 mg/kg.
Showed no significant body weight loss or organ toxicity in either dose group.
Chemical Information
-
Masse moléculaire 640.78
-
Formule C38H40N8O2
-
SMILES
CC1=C(C2=NC(OC)=C(CNC3CCN(C(CCCN4C=C(C5=NC=NC6=C5C=CN6)C=N4)=O)CC3)C=C2)C=CC=C1C7=CC=CC=C7
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PJ27 Related Classifications
HY-181663 Related Classifications
Powered by Bioz